Evaluation of second-line apatinib plus irinotecan as a treatment for advanced gastric adenocarcinoma or gastroesophageal conjunction adenocarcinoma: a prospective, multicenter phase II trial

ObjectiveApatinib and irinotecan are used as systematic therapies for advanced gastric adenocarcinoma (GAC) and gastroesophageal junction adenocarcinoma (GEJA), while the evidence for their combination as second-line therapy in these patients is limited. This study aimed to evaluate the efficacy and...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Jinglei Qu, Xin He, Ying Luo, Ping Yu, Ying Chen, Jing Liu, Xin Wang, Chang Wang, Tingting Liang, Yuxian Bai, Yu Han, Li Man, Chuanchun Leng, Caiyun Zhou, Lijie He, Yunpeng Liu, Xiujuan Qu
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Frontiers Media S.A. 2023-04-01
Reeks:	Frontiers in Oncology
Onderwerpen:	second-line apatinib plus irinotecan gastric adenocarcinoma gastroesophageal junction adenocarcinoma treatment efficacy safety
Online toegang:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1072943/full
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!